440 related articles for article (PubMed ID: 36521952)
21. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
[TBL] [Abstract][Full Text] [Related]
22. Implementation of a human papillomavirus vaccination demonstration project in Malawi: successes and challenges.
Msyamboza KP; Mwagomba BM; Valle M; Chiumia H; Phiri T
BMC Public Health; 2017 Jun; 17(1):599. PubMed ID: 28651574
[TBL] [Abstract][Full Text] [Related]
23. Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model.
Jit M; Brisson M; Laprise JF; Choi YH
BMJ; 2015 Jan; 350():g7584. PubMed ID: 25567037
[TBL] [Abstract][Full Text] [Related]
24. Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial.
Baisley K; Kemp TJ; Kreimer AR; Basu P; Changalucha J; Hildesheim A; Porras C; Whitworth H; Herrero R; Lacey CJ; Schiller JT; Lucas E; Mutani P; Dillner J; Indangasi J; Muwonge R; Hayes RJ; Pinto LA; Watson-Jones D
Lancet Glob Health; 2022 Oct; 10(10):e1485-e1493. PubMed ID: 36113532
[TBL] [Abstract][Full Text] [Related]
25. Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study.
Castanon A; Landy R; Pesola F; Windridge P; Sasieni P
Lancet Public Health; 2018 Jan; 3(1):e34-e43. PubMed ID: 29307386
[TBL] [Abstract][Full Text] [Related]
26. A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing Tool.
Hutubessy R; Levin A; Wang S; Morgan W; Ally M; John T; Broutet N
BMC Med; 2012 Nov; 10():136. PubMed ID: 23146319
[TBL] [Abstract][Full Text] [Related]
27. Health and economic effects of introducing single-dose or two-dose human papillomavirus vaccination in India.
M de Carvalho T; Man I; Georges D; Saraswati LR; Bhandari P; Kataria I; Siddiqui M; Muwonge R; Lucas E; Sankaranarayanan R; Basu P; Berkhof J; Bogaards JA; Baussano I
BMJ Glob Health; 2023 Nov; 8(11):. PubMed ID: 37931940
[TBL] [Abstract][Full Text] [Related]
28. Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland.
Kind AB; Pavelyev A; Kothari S; El Mouaddin N; Schmidt A; Morais E; Guggisberg P; Lienert F
BMC Public Health; 2020 May; 20(1):671. PubMed ID: 32398057
[TBL] [Abstract][Full Text] [Related]
29. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study.
Basu P; Malvi SG; Joshi S; Bhatla N; Muwonge R; Lucas E; Verma Y; Esmy PO; Poli URR; Shah A; Zomawia E; Pimple S; Jayant K; Hingmire S; Chiwate A; Divate U; Vashist S; Mishra G; Jadhav R; Siddiqi M; Sankaran S; Prabhu PR; Kannan TPRA; Varghese R; Shastri SS; Anantharaman D; Gheit T; Tommasino M; Sauvaget C; Pillai MR; Sankaranarayanan R
Lancet Oncol; 2021 Nov; 22(11):1518-1529. PubMed ID: 34634254
[TBL] [Abstract][Full Text] [Related]
30. A modelled analysis of the impact of COVID-19-related disruptions to HPV vaccination.
Velentzis LS; Smith MA; Killen J; Brotherton JML; Guy R; Canfell K
Elife; 2023 Oct; 12():. PubMed ID: 37831501
[TBL] [Abstract][Full Text] [Related]
31. Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models.
Jit M; Demarteau N; Elbasha E; Ginsberg G; Kim J; Praditsitthikorn N; Sinanovic E; Hutubessy R
BMC Med; 2011 May; 9():54. PubMed ID: 21569406
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial.
Watson-Jones D; Changalucha J; Whitworth H; Pinto L; Mutani P; Indangasi J; Kemp T; Hashim R; Kamala B; Wiggins R; Songoro T; Connor N; Mbwanji G; Pavon MA; Lowe B; Mmbando D; Kapiga S; Mayaud P; de SanJosé S; Dillner J; Hayes RJ; Lacey CJ; Baisley K
Lancet Glob Health; 2022 Oct; 10(10):e1473-e1484. PubMed ID: 36113531
[TBL] [Abstract][Full Text] [Related]
33. Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths.
Van Kriekinge G; Castellsagué X; Cibula D; Demarteau N
Vaccine; 2014 Feb; 32(6):733-9. PubMed ID: 24291200
[TBL] [Abstract][Full Text] [Related]
34. Estimating the health effects of COVID-19-related immunisation disruptions in 112 countries during 2020-30: a modelling study.
Hartner AM; Li X; Echeverria-Londono S; Roth J; Abbas K; Auzenbergs M; de Villiers MJ; Ferrari MJ; Fraser K; Fu H; Hallett T; Hinsley W; Jit M; Karachaliou A; Moore SM; Nayagam S; Papadopoulos T; Perkins TA; Portnoy A; Minh QT; Vynnycky E; Winter AK; Burrows H; Chen C; Clapham HE; Deshpande A; Hauryski S; Huber J; Jean K; Kim C; Kim JH; Koh J; Lopman BA; Pitzer VE; Tam Y; Lambach P; Sim SY; Woodruff K; Ferguson NM; Trotter CL; Gaythorpe KAM
Lancet Glob Health; 2024 Apr; 12(4):e563-e571. PubMed ID: 38485425
[TBL] [Abstract][Full Text] [Related]
35. Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia.
Regan DG; Philp DJ; Hocking JS; Law MG
Sex Health; 2007 Sep; 4(3):147-63. PubMed ID: 17931528
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of human papillomavirus vaccination and screening in Spain.
Diaz M; de Sanjose S; Ortendahl J; O'Shea M; Goldie SJ; Bosch FX; Kim JJ
Eur J Cancer; 2010 Nov; 46(16):2973-85. PubMed ID: 20638840
[TBL] [Abstract][Full Text] [Related]
37. Costs and cost-effectiveness of 9-valent human papillomavirus (HPV) vaccination in two East African countries.
Kiatpongsan S; Kim JJ
PLoS One; 2014; 9(9):e106836. PubMed ID: 25198104
[TBL] [Abstract][Full Text] [Related]
38. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models.
Brisson M; Bénard É; Drolet M; Bogaards JA; Baussano I; Vänskä S; Jit M; Boily MC; Smith MA; Berkhof J; Canfell K; Chesson HW; Burger EA; Choi YH; De Blasio BF; De Vlas SJ; Guzzetta G; Hontelez JAC; Horn J; Jepsen MR; Kim JJ; Lazzarato F; Matthijsse SM; Mikolajczyk R; Pavelyev A; Pillsbury M; Shafer LA; Tully SP; Turner HC; Usher C; Walsh C
Lancet Public Health; 2016 Nov; 1(1):e8-e17. PubMed ID: 29253379
[TBL] [Abstract][Full Text] [Related]
39. Two-dose schedules for human papillomavirus vaccine: Systematic review and meta-analysis.
D'Addario M; Redmond S; Scott P; Egli-Gany D; Riveros-Balta AX; Henao Restrepo AM; Low N
Vaccine; 2017 May; 35(22):2892-2901. PubMed ID: 28455170
[TBL] [Abstract][Full Text] [Related]
40. Impact, cost-effectiveness, and budget implications of HPV vaccination in Kenya: A modelling study.
Mwenda V; Jalang'o R; Miano C; Bor JP; Nyangasi M; Mecca L; Were V; Kariithi E; Pecenka C; Schuind A; Abbas K; Clark A
Vaccine; 2023 Jun; 41(29):4228-4238. PubMed ID: 37296015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]